LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Inclusion Criteria:

• Age 18 years or above

• Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitalsand skin folds) involving 2-30% of the Body Surface Area (BSA)

• A Physician's Global Assessment of disease severity (PGA) of at least mild on trunkand limbs

• A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk andlimbs.

Exclusion Criteria:

• Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

• Systemic treatment with biological therapies, whether marketed or not, with apossible effect on psoriasis vulgaris within the following time periods prior torandomisation:

• etanercept - within 4 weeks prior to randomisation

• adalimumab, infliximab - within 8 weeks prior to randomisation

• ustekinumab - within 16 weeks prior to randomisation

• other products - within 4 weeks/5 half-lives prior to randomisation (whicheveris longer)

• Systemic treatment with all other therapies with a possible effect on psoriasisvulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and otherimmunosuppressants within 4 weeks prior to randomisation)

• Subjects who have received treatment with any non-marketed drug substance (i.e. adrug which has not yet been made available for clinical use following registration)within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.

• Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior torandomisation

• Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation

• Topical anti-psoriatic treatment on the trunk and limbs (except for emollients)within 2 weeks prior to randomisation

• Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin Danalogues or prescription shampoos within 2 weeks prior to randomisation

• Females who are pregnant, wishing to become pregnant during the trial or arebreastfeeding